STOCK TITAN

AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)

Amgen (NASDAQ:AMGN) has released a statement regarding the Phase 1 data of MariTide (maridebart cafraglutide, formerly AMG 133). The company affirms there is no apparent connection between MariTide administration and bone mineral density changes. Amgen maintains that the Phase 1 study results do not indicate any bone safety concerns and do not affect their confidence in MariTide's potential. The company plans to release Phase 2 topline data later this year.

Amgen (NASDAQ:AMGN) ha rilasciato una dichiarazione riguardo ai dati della Fase 1 di MariTide (maridebart cafraglutide, precedentemente noto come AMG 133). L'azienda afferma che non vi è apparente collegamento tra l'amministrazione di MariTide e i cambiamenti nella densità minerale ossea. Amgen sostiene che i risultati dello studio di Fase 1 non indicano preoccupazioni relative alla sicurezza ossea e non influenzano la loro fiducia nel potenziale di MariTide. L'azienda prevede di pubblicare i dati preliminari della Fase 2 entro la fine di quest'anno.

Amgen (NASDAQ:AMGN) ha emitido un comunicado sobre los datos de la Fase 1 de MariTide (maridebart cafraglutide, anteriormente AMG 133). La compañía afirma que no existe una conexión aparente entre la administración de MariTide y los cambios en la densidad mineral ósea. Amgen sostiene que los resultados del estudio de la Fase 1 no indican problemas de seguridad ósea y no afectan su confianza en el potencial de MariTide. La compañía planea publicar los datos preliminares de la Fase 2 más adelante este año.

Amgen (NASDAQ:AMGN)MariTide (maridebart cafraglutide, 이전 AMG 133)의 1상 데이터에 대한 발표를 했습니다. 회사는 MariTide 투여와 골밀도 변화 사이에 명백한 연결고리가 없다고 밝혔습니다. Amgen은 1상 연구 결과가 뼈의 안전성을 우려할 만한 것이 아니며, MariTide의 잠재력에 대한 신뢰에 영향을 미치지 않는다고 주장합니다. 회사는 올해 말에 2상 주요 데이터를 발표할 계획입니다.

Amgen (NASDAQ:AMGN) a publié une déclaration concernant les données de la Phase 1 de MariTide (maridebart cafraglutide, anciennement AMG 133). La société affirme qu’il n’existe pas de lien apparent entre l’administration de MariTide et les changements de densité minérale osseuse. Amgen soutient que les résultats de l'étude de Phase 1 n'indiquent aucune préoccupation en matière de sécurité osseuse et n'affectent pas leur confiance dans le potentiel de MariTide. L'entreprise prévoit de publier les données préliminaires de la Phase 2 plus tard cette année.

Amgen (NASDAQ:AMGN) hat eine Erklärung zu den Phase-1-Daten von MariTide (maridebart cafraglutide, früher bekannt als AMG 133) abgegeben. Das Unternehmen bestätigt, dass es keine offensichtliche Verbindung zwischen der Anwendung von MariTide und Veränderungen der Knochendichte gibt. Amgen betont, dass die Ergebnisse der Phase-1-Studie keine Bedenken hinsichtlich der Knochensicherheit aufzeigen und ihr Vertrauen in das Potenzial von MariTide nicht beeinträchtigen. Das Unternehmen plant, später in diesem Jahr die vorläufigen Daten der Phase 2 zu veröffentlichen.

Positive
  • No bone safety concerns identified in Phase 1 trial
  • Phase 2 topline data release scheduled for later this year
Negative
  • None.

Insights

The Phase 1 safety statement regarding MariTide (maridebart cafraglutide) addresses a critical concern in the obesity treatment landscape. Bone mineral density changes have been a significant focus in weight loss medications, particularly given the experiences with other GLP-1 drugs. While this statement affirms no concerning safety signals, the real value proposition remains contingent on the upcoming Phase 2 data.

The statement's timing suggests a proactive response to market concerns, but offers new information. Phase 1 data typically focuses on safety and tolerability in small patient populations, making it preliminary in nature. The upcoming Phase 2 results will be far more decisive in determining MariTide's competitive positioning in the rapidly evolving obesity treatment market.

THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.

"As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data later this year."

Amgen Forward-Looking Statements
This communication contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this communication and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future.

Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors) 

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-provides-statement-on-maritide-phase-1-data-302303750.html

SOURCE Amgen

FAQ

What did Amgen (AMGN) say about MariTide's Phase 1 bone safety data?

Amgen stated there is no association between MariTide administration and bone mineral density changes, with Phase 1 results showing no bone safety concerns.

When will Amgen (AMGN) release MariTide Phase 2 data?

Amgen plans to release MariTide Phase 2 topline data later in 2024.

What is the new name for Amgen's AMG 133 drug?

AMG 133 has been renamed to MariTide (maridebart cafraglutide).

Amgen Inc

NASDAQ:AMGN

AMGN Rankings

AMGN Latest News

AMGN Stock Data

157.01B
535.91M
0.25%
80.88%
1.64%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS